Document Type
Article
Journal Title
Journal of the American College of Emergency Physicians Open
Publication Date
2024
Volume
5
Abstract
OBJECTIVES: This study describes clinical characteristics and management strategies for patients with factor Xa (FXa) inhibitor-related traumatic non-intracranial bleeds who were treated with andexanet alfa or four-factor prothrombin complex concentrate (4F-PCC).
METHODS: An observational cohort study (ClinicalTrials.gov Identifier: NCT05548777) was conducted using electronic health records from 354 US hospitals. Included patients were hospitalized with rivaroxaban- or apixaban-related bleeding, had received andexanet alfa or 4F-PCC treatment during their hospitalization, and were discharged between May 2018 and September 2022. This analysis was performed in the subgroup of patients with traumatic non-intracranial critical compartment/non-compressible bleeds or other traumatic bleeds.
RESULTS: The study population included 250 patients (andexanet alfa,
CONCLUSION: This analysis provides insights into the clinical characteristics and management strategies, including time to treatment, for patients treated with andexanet alfa or 4F-PCC while hospitalized for FXa inhibitor-related traumatic bleeds.
DOI Link
ISSN
2688-1152
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Dobesh, Paul P.; Coleman, Craig I.; Danese, Mark; Lesén, Eva; Chang, Raymond C.; Odelade, Onivefu; and Fermann, Gregory J., "Management of Factor Xa Inhibitor-Related Traumatic Non-Intracranial Bleeding Events with Andexanet Alfa or Four-Factor Prothrombin Complex Concentrate in a US Multicenter Observational Study" (2024). Journal Articles: Pharmacy Practice. 10.
https://digitalcommons.unmc.edu/cop_pharmpract_articles/10